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DOI 10.1016/j.chembiol.2011.02.006Locked inside the brain of a child with
autism spectrum disorder is a person
who cannot tell his mother when he has
a sore throat, or a stomachache, or why
some days he needs a pile of toy train
engines just to feel safe. Put those same
children in a clinical trial in which the
outcome measure follows changes in
behavior and it’s easy to see why devel-
oping a treatment for autism spectrum
disorder (ASD) has proven so thorny.
For starters, scientists still do not have
a clear idea of the genetic pathways that
lead to ASD. The impact of autism’s core
symptoms—repetitive behavior, social
impairment, and communication difficul-
ties—can vary widely. Even though these
symptoms all describe behavior, ASD‘‘It’s possible that one family’s version of autismmay be treatable
in a way that no one else’s is.’’ — John Constantino, M.D.affects the whole body. As with other
developmental disorders, people with
ASD can suffer from gastrointestinal
problems, seizure disorders or immune
deficiencies. When that heterogeneity is
multiplied by 1.5 million within the United
States, it isnowonder themedical commu-
nity needs threewords—autism spectrum
disorder—just to describe the condition.
Most of the work in autism therapeutics
has been geared toward intervention.
In 2009, the U.S. Food and Drug Adminis-
tration approved Bristol-Meyers Squibb’s
ABILIFY (aripiprazole) for treatment of
irritability and aggression in autism.
Risperidone, originally manufactured by
Janssen L.P., now available as a generic,
is used for the same reason. These drugs
help with outbursts and tantrums, but do
not address the core symptoms of autism
and ASD.
Some compounds to treat ASD’s core
symptoms have made it to clinical trials.
A few years ago, the now-defunct Neuro-
pharm LTD teamed up with the advocacy142 Chemistry & Biology 18, February 25, 201organization Autism Speaks for a clinical
trial to test a low dose of PROZAC (fluox-
etine) aimed at repetitive behaviors.
Unfortunately, the trial found no differ-
ences between treatment and placebo.
The PROZAC trial may have failed, but it
remains significant because it was the
first autism treatment given the FDA Fast
Track designation, a process designed
to test potential therapeutics that address
an unmet need. Clara Lajonchere, vice
president of clinical programs for Autism
Speaks, says the failed trial laid the
groundwork for other companies to seek
Fast Track approval for ASD.
Because ASD is so heterogeneous,
children with ASD show a wide variety of
symptoms and their response to treat-ment is so variable, making it hard to say
definitively whether a drug ‘‘works’’ or
not. ‘‘It’s possible that one family’s
version of autism may be treatable in
a way that no one else’s is,’’ says John
Constantino, M.D., a professor of pedi-
atric psychiatry at Washington University
in St. Louis, Missouri.
Complex Disease, Difficult Issues
The difference among different autism
spectrum disorders lies in the severity of
symptoms. So many genetic pathways
have been implicated in autism spec-
trum disorders that Bryan King, M.D.,
a professor of psychiatry at the University
of Washington, Seattle, comments that
many clinicians and investigators now
refer to the condition as ‘‘autisms’’
because it is hard to pin down a single
target for a single drug treatment that
can address such diverse biochemical
pathways. Still, saysKing, ‘‘there is reason
to believe we may find a compound that
does improve repetitive behaviors in1 ª2011 Elsevier Ltd All rights reservedautism or does improve some measure
of social interaction. As genetic pathways
are found to converge, the target list for
innovative treatments will become more
focused.’’
Interest from pharma has grown in the
past few years. Two companies have
begun clinical trials on drugs that aim for
core symptoms, using vastly different
approaches.
One is the Rye, New York, based Cure-
mark, which has an enzyme replacement
therapy ready to start a randomized
double blind, placebo-controlled Phase
III clinical trial. Curemark founder and
CEO Joan Fallon, D.C., first came in
contact with ASD in her chiropractic prac-
tice in the early 1990s, when parents
brought in children with developmental
problems.
Fallon says many parents remarked
that their children with developmental
disabilities favored carbohydrates over
protein. She analyzed the children’s blood
and urine and found that they lacked the
digestive enzyme chymotrypsin, which
splits peptide amide bonds, thus digest-
ing a protein. With private funding, she
and colleagues came up with a way to
orally deliver high levels of chymotrypsin.
The company is nearly ready to recruit
patients for its Phase III trial. Once the
clinical trial ends, Fallon says she and
her colleagues will analyze the data
and then seek a partnership with a large,
specialty pharmaceutical company.
‘‘Hopefully this might help some children
and it will give new light to the physiology
of autism and perhaps it will spur other
research,’’ says Fallon.
King is cautious about Curemark’s
prospects. One of the basic principles
guiding medical research is that associa-
tion does not mean causation. So the
observation that children with autism or
ASD lack chymotrypsin may be unrelated
to what causes the disease. ‘‘It’s not
always the case that what we think
we’re doing for intervention is actually
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King, whose institution is not part of Cure-
mark’s clinical trials. On the flip side, King
says, ‘‘Curemark’s approach is certainly
different from many others, but they are
doing studies; others have simply as-
serted that their treatment works.’’
The ‘‘X’’ Files
The second therapy starting Phase II clin-
ical trials for ASD came from studies done
on Fragile X Syndrome, a developmental
disorder caused by a mutation in a single
gene, which can also cause autism.
People with this condition cannot make
fragile X mental retardation protein
(FMRP), a protein that is critical for brain
development and for establishing
synaptic connections. FMRP exerts
some of the function by regulating
a metabotropic glutamate receptor
(mGluR) and, indirectly, mGluR-depen-
dent protein synthesis. Mark Bear, Ph.D.,
an HHMI researcher at MIT, mapped
Fragile X pathways in a genetically engi-
neered Fragile X mouse. In 2005, Bear
and Randall Carpenter, M.D., initially
founded Seaside Therapeutics through
private funding, and then later, through
NIH grants and patient advocacy organi-
zations, including Autism Speaks.
Seaside Therapeutics licensed
a compound from Merck that normalizes
activity in this critical signaling pathway
and began clinical trials to treat Fragile
X. Today the company is testing two
candidates for Fragile X, autism, and ASD.
Carpenter says the company is working
to understand the molecular pathophysi-
ology behind these developmental disor-
ders and then trying to normalize those
pathways through targeted treatments.
These pathways link areas of the brain
that control synaptic plasticity for
learning. As the brain develops, connec-
tions between synapses strengthen
when responding to important informa-
tion and weaken in response to noise.This delicate balance in the signal-
to-noise ratio appears to be dysregulated
in Fragile X and autism spectrum
disorders.
The theory is thatweall learn fromexpe-
rience, but people with developmental
disorders do not learn from experience at
the same rate or level. Consequently, chil-
dren with Fragile X or those along the
autism spectrum may have delays in
reaching developmental milestones such
as sitting up, walking, or talking, or may
never reach certain milestones such as
social awareness, or master such skills
as higher math or reading. Carpenter
says targeted therapeutics can potentially
restore the balance between signal and
noise, thereby retuning the brain and
improving learning. The compounds that
Seaside Therapeutics has in clinical trials
have so far shown improvement in
behavior. With more long-term treatment
(at least longer than the two or three
months for a clinical trial), Carpenter
hopes function will improve.
‘‘You’re not going to raise IQ in a four-
week trial,’’ says Carpenter. ‘‘Our goal is
not to turn everyone into Einstein, but to
allow people to be functional contributing
members of society who can live
independently.’’
It Takes a Really Big Village
Such efforts do not happen in isolation.
Until relatively recently, academic
researchers studied autism through the
confines of their respective specialties.
Ultimately, universities began organizing
autism researchers into communities of
scientists from wide ranging disciplines.
The NIH funds collaborative research
through their Autism Centers of Excel-
lence program. Early on, according to
Carpenter, Seaside Therapeutics care-
fully laid the groundwork for a diverse
group of collaborators.
Marguerite Colston, spokesperson for
the Autism Society, a U.S. grassrootsChemistry & Biology 18, February 25, 2011autism organization, and the parent of
a son with autism, sees value in collecting
anecdotes from parents. Colston keeps
a daily log of what her son eats, his toilet-
ing schedule, and what he did in school.
Many parents, she says, can offer an
untapped resource of useful observa-
tions. ‘‘We want to build a database of
anecdotal data, which can be de-
identified,’’ says Colston. The Autsim
Society would then use that database to
get more funding for research into
treatment.
Recently, Autism Speaks launched two
collaborative efforts, says Lajonchere. In
late 2010, the organization teamed with
Sigma Life Sciences to create a number
of knockout rat models that simulate
various symptoms and pathologies of
autism. In January 2011, Autism Speaks
launched their Translational Medicine
Initiative, bringing together a wide repre-
sentation of experts from academia,
pharma, industry partners, and the federal
government.
Lajonchere says that one goal of this
initiative is to develop strategies for novel
clinical trial design that includes the iden-
tification and development of additional
outcome measures that are more sensi-
tive to change. The initiative also hopes
to develop long-term close collaboration
with researchers in the preclinical area
and encourage dialog with the clinicians
and researchers on the other end of the
pipeline. Several pharmaceutical compa-
nies have demonstrated a willingness to
share compounds for potential new thera-
pies once researchers are able to identify
viable targets.
‘‘Collaboration and open dialogue are
keys in translational medicine. Bringing
together the entire research community
will provide the best way forward,’’ says
Lajonchere.Jeanne Erdmann (erdmannj@nasw.org) is a
science writer based in Wentzville, MO.ª2011 Elsevier Ltd All rights reserved 143
